Countries expand nonprescription sales: Italy and Hungary ease regulations for sales of nonprescription drugs. Drug companies and stores in Italy now can price nonprescription drugs as they wish as long as the amounts do not exceed prices set in December 2006 and are visible at points of sale, Guido Rasi, director general of the Italian Medicines Agency, said at the Association of the European Self-Medication Industry's (AESGP) Nov. 5 conference in Paris. Rasi added that retail prices also can be discounted. Through October 2008 in Hungary, 701 licensed non-pharmacy outlets were selling nonprescription products, including analgesics and vitamins, said Zsuzanna Szepezdi, director general of the country's National Institute of Pharmacy. She explained that Hungary eased nonprescription sales regulations in early 2007 so that some products can be sold outside the pharmacy if they are stored in closed cupboards and information about the products is available via electronic information systems
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
The removal of CBER Director Prasad comes after a wave of right-wing backlash to his appointment over the past few days that was also critical of his decision to ask Sarepta to suspend all sales of the DMD gene therapy Elevidys. FDA reversed its decision the day before Parsad's departure.
Meanwhile, companies continue discussions with the Trump Administration over ways of increasing what European nations pay for drugs as an alternative to imposing a Most Favored Nation drug pricing policy in the US.
